Axsome Therapeutics, Inc.
$129.36-$6.32 (-4.7%)
Last close · Data as of Nov 20, 2026
- Market cap
- $11.9B
- P/E
- -65.0x
- EV / EBITDA
- -70.2x
- Revenue
- $638.5M
- Net margin
- -28.7%
- ROCE
- -54.4%
Price chart
Technical chartScreen technicals →-9.7% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -18.9%
- 3M
- -37.8%
- 6M
- -43.9%
- 1Y
- -9.7%
- 5Y
- +261.3%
52-week range
Day change -$6.32 (-4.7%) from $136 to $129 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in AXSM, bought on each weekday since 2021.
News & filings
What Axsome Therapeutics filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 183 million US dollars in fiscal 2025.
Strengths (1)
- Revenue grew 65.5% in fiscal 2025.
- Shareholders' equity is small against the company's size, so return on equity and debt to equity are not shown.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
Read moreShow less
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.
- Sector
- Healthcare
- Shares outstanding
- 50.9M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $11.9B
- P/E
- -65.0x
- P/B
- 134.9x
- EV / EBITDA
- -70.2x
- EV / Sales
- 18.5x
- P/S
- 18.7x
- 52-week high
- $255.17
- 52-week low
- $129.36
Profitability
- Operating margin
- -26.5%
- Net margin
- -28.7%
- EBITDA margin
- -26.3%
- ROE
- -207.5%
- ROCE
- -54.4%
- ROA
- -26.6%
- Asset turnover
- 0.93
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $638.5M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 65.5%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 133.7%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -36.2%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$93.9M
Solvency
- Current ratio
- 1.55
- Debt / Equity
- 2.47
- Debt / Assets
- 0.32
- CFO / Net profit
- 0.51
- Cash / Market cap
- 2.7%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $638.5M |
| Cost of revenue | $47.5M |
| Gross profit | $591.0M |
| Operating expenses | $760.3M |
| Research and development | $183.3M |
| Selling, general and administrative | $570.6M |
| Operating income | -$169.2M |
| Interest and other | -$14.5M |
| Pretax income | -$183.7M |
| Tax and other | -$530.0k |
| Net income | -$183.2M |
Revenue and net profit
Revenue grew 65.5% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $50.0M | -$187.1M |
| FY2023 | $270.6M | -$239.2M |
| FY2024 | $385.7M | -$287.2M |
| FY2025 | $638.5M | -$183.2M |
Cash flows
FY2025: -$93.4M from operations, -$93.9M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$116.5M | -$117.2M |
| FY2023 | -$145.1M | -$145.7M |
| FY2024 | -$128.4M | -$128.7M |
| FY2025 | -$93.4M | -$93.9M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $638.5M+65.5%1Y
- EBITDA
- -$168.1M
- Net profit
- -$183.2M
- Cash from operations
- -$93.4M
- Free cash flow
- -$93.9M
- Revenue CAGR, 3Y
- 133.7%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $638.5M | -$168.1M | -$183.2M | -$93.9M | -207.5% | +65.5% | -36.2% |
Monthly returns
Month-by-month returns of AXSM across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $689.8M |
| Current assets | $589.0M |
| Non-current assets | $100.8M |
| Liabilities | $601.5M |
| Current liabilities | $378.8M |
| Non-current liabilities | $222.7M |
| Equity | $88.3M |
| Paid-in capital | $1.4B |
| Retained earnings | -$1.3B |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; AXSM highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Nuvalent, Inc., Praxis Precision Medicines, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc.AXSMthis company | $11.9B | -65.0x | 134.9x | -207.5% | -70.2x |
| BridgeBio Pharma, Inc.BBIO | $13.2B | -18.2x | -6.3x | 34.7% | -26.4x |
| Madrigal Pharmaceuticals, Inc.MDGL | $11.4B | -39.4x | 18.9x | -47.8% | -43.5x |
| Arrowhead Pharmaceuticals, Inc.ARWR | $10.6B | -6491.0x | 22.7x | -0.3% | 65.9x |
| Cytokinetics, IncorporatedCYTK | $9.8B | — | — | 119.0% | — |
| The Ensign Group, Inc.ENSG | $9.6B | 27.9x | 4.3x | 15.4% | 19.9x |
| ImmunityBio, Inc.IBRX | $7.6B | -21.7x | -15.3x | 70.2% | -36.1x |
| Nuvalent, Inc.NUVL | $7.4B | -17.5x | 5.9x | -34.1% | — |
| Praxis Precision Medicines, Inc.PRAX | $7.4B | -24.3x | 8.4x | -34.5% | -21.5x |
| Peer median | — | -21.7x | 5.9x | 7.5% | -24.0x |
Year-to-date ROI
AXSM since 1 January, against earlier years.
Historical volatility
AXSM's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -352.7% |
| FY2023 | -67.6% |
| FY2024 | -65.5% |
| FY2025 | -26.5% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $638.5M |
| Cost of revenueCost Of Revenue | $47.5M |
| Gross profitGross Profit | $591.0M |
| Operating expensesOperating Expense | $760.3M |
| Research and developmentResearch And Development | $183.3M |
| Selling, general and administrativeSelling General And Administration | $570.6M |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $6.4M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $6.4M |
| Amortization | $6.4M |
| Amortisation of intangiblesAmortization Of Intangibles Income Statement | $6.4M |
| Total expensesTotal Expenses | $807.7M |
| Operating incomeOperating Income | -$169.2M |
| Interest and other | |
| Pretax incomePretax Income | -$183.7M |
| TaxTax Provision | -$530.0k |
| Net incomeNet Income | -$183.2M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $689.8M |
| Current assetsCurrent Assets | $589.0M |
| Non-current assetsTotal Non Current Assets | $100.8M |
| LiabilitiesTotal Liabilities Net Minority Interest | $601.5M |
| Current liabilitiesCurrent Liabilities | $378.8M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $222.7M |
| EquityTotal Equity Gross Minority Interest | $88.3M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$93.4M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$93.4M |
| Net income, continuing operationsNet Income From Continuing Operations | -$183.2M |
| Depreciation and amortisationDepreciation And Amortization | $9.1M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $9.1M |
| Depreciation | $2.7M |
| Amortization cash flowAmortization Cash Flow | $6.4M |
| Amortization of intangiblesAmortization Of Intangibles | $6.4M |
| Stock-based compensationStock Based Compensation | $93.8M |
| Operating gains and lossesOperating Gains Losses | $10.4M |
| Change in working capitalChange In Working Capital | -$22.5M |
| Other non-cash itemsOther Non Cash Items | -$910.0k |
| Investing cash flowInvesting Cash Flow | -$480.0k |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$480.0k |
| Capital expenditureCapital Expenditure | -$480.0k |
| Purchase of PP&EPurchase Of PPE | -$480.0k |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$480.0k |
| AcquisitionsPurchase Of Business | — |
| Net acquisitions and disposalsNet Business Purchase And Sale | — |
| Financing cash flowFinancing Cash Flow | $101.5M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $101.5M |
| Debt issuedIssuance Of Debt | $330.0M |
| Debt repaidRepayment Of Debt | -$334.1M |
| Net debt issuedNet Issuance Payments Of Debt | -$4.1M |
| Long-term debt issuedLong Term Debt Issuance | $330.0M |
| Long-term debt repaidLong Term Debt Payments | -$334.1M |
| Net long-term debt issuedNet Long Term Debt Issuance | -$4.1M |
| Shares issuedIssuance Of Capital Stock | $67.9M |
| Common stock issuedCommon Stock Issuance | $67.9M |
| Net common stock issuedNet Common Stock Issuance | $67.9M |
| Stock options exercisedProceeds From Stock Option Exercised | $59.6M |
| Other financing chargesNet Other Financing Charges | -$21.9M |
| Change in cashChanges In Cash | $7.6M |
| Cash at the start of the yearBeginning Cash Position | $315.4M |
| Cash at the end of the yearEnd Cash Position | $322.9M |
| Free cash flowFree Cash Flow | -$93.9M |
| Supplemental |
Learn while you research
Academy chapters picked for Axsome Therapeutics, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Growth Investing66% revenue growth is in the top tier, learn how to value growth.7 min read
- 03 Leverage RatiosDebt/Equity of 2.47 is elevated, understand what that means for solvency.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read